相似文献
1
The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.
J Virol. 2012 Jun;86(11):6279-85. doi: 10.1128/JVI.00123-12. Epub 2012 Apr 4.
2
Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5.
Int J Pharm. 2024 Sep 5;662:124480. doi: 10.1016/j.ijpharm.2024.124480. Epub 2024 Jul 20.
3
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.
J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.
4
Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.
J Immunol. 2007 Aug 1;179(3):1721-9. doi: 10.4049/jimmunol.179.3.1721.
5
Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
J Virol. 2012 Jan;86(2):1267-72. doi: 10.1128/JVI.06165-11. Epub 2011 Nov 9.
6
Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.
J Virol. 2012 Jan;86(1):625-9. doi: 10.1128/JVI.06254-11. Epub 2011 Nov 9.
7
Trimeric knob protein specifically distinguishes neutralizing antibodies to different human adenovirus species: potential application for adenovirus seroepidemiology.
J Gen Virol. 2014 Jul;95(Pt 7):1564-1573. doi: 10.1099/vir.0.064832-0. Epub 2014 Apr 24.
8
Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial.
Mol Ther. 2020 Mar 4;28(3):784-793. doi: 10.1016/j.ymthe.2020.01.006. Epub 2020 Feb 7.
9
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.
J Virol. 2003 Aug;77(15):8263-71. doi: 10.1128/jvi.77.15.8263-8271.2003.
10
Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.
J Exp Med. 2008 Nov 24;205(12):2717-25. doi: 10.1084/jem.20081786. Epub 2008 Nov 3.
引用本文的文献
1
Comparative analysis of the impact of 40 adenovirus types on dendritic cell activation and CD8 T cell proliferation capacity for the identification of favorable immunization vector candidates.
Front Immunol. 2023 Oct 17;14:1286622. doi: 10.3389/fimmu.2023.1286622. eCollection 2023.
2
The use of adenoviral vectors in gene therapy and vaccine approaches.
Genet Mol Biol. 2022 Oct 7;45(3 Suppl 1):e20220079. doi: 10.1590/1678-4685-GMB-2022-0079. eCollection 2022.
3
Human Adenovirus Species D Interactions with Corneal Stromal Cells.
Viruses. 2021 Dec 14;13(12):2505. doi: 10.3390/v13122505.
4
IgG-Complexed Adenoviruses Induce Human Plasmacytoid Dendritic Cell Activation and Apoptosis.
Viruses. 2021 Aug 27;13(9):1699. doi: 10.3390/v13091699.
5
Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.01155-19. Print 2019 Nov 1.
6
Impact of dynamin 2 on adenovirus nuclear entry.
Virology. 2019 Mar;529:43-56. doi: 10.1016/j.virol.2019.01.008. Epub 2019 Jan 10.
7
Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human Dendritic Cells.
PLoS Pathog. 2016 Sep 16;12(9):e1005871. doi: 10.1371/journal.ppat.1005871. eCollection 2016 Sep.
8
Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.
Mol Ther. 2016 Feb;24(1):6-16. doi: 10.1038/mt.2015.194. Epub 2015 Oct 19.
9
Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.
J Clin Invest. 2015 Mar 2;125(3):1129-46. doi: 10.1172/JCI78280. Epub 2015 Feb 2.
10
Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells.
J Virol. 2014 Dec;88(24):14426-39. doi: 10.1128/JVI.02608-14. Epub 2014 Oct 8.
本文引用的文献
1
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.
J Clin Invest. 2012 Jan;122(1):359-67. doi: 10.1172/JCI60202. Epub 2011 Dec 27.
2
Rare serotype adenoviral vectors for HIV vaccine development.
J Clin Invest. 2012 Jan;122(1):25-7. doi: 10.1172/JCI60988. Epub 2011 Dec 27.
3
Modulation of human memory T-cell function by different antigen-presenting cells.
Eur J Immunol. 2012 Mar;42(3):799-802. doi: 10.1002/eji.201142094. Epub 2011 Dec 20.
4
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.
Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.
5
Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7499-504. doi: 10.1073/pnas.1017146108. Epub 2011 Apr 18.
6
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.
J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.
7
HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells.
Nat Immunol. 2010 May;11(5):419-26. doi: 10.1038/ni.1858. Epub 2010 Apr 4.
8
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.
Vaccine. 2010 Jan 22;28(4):950-7. doi: 10.1016/j.vaccine.2009.10.145. Epub 2009 Nov 17.
9
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.
Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.
10
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.
Zotero 插件